Overview
Myelitis caused by bacterial infection refers to inflammation of the spinal cord secondary to bacterial invasion, often leading to significant neurological deficits. This condition can arise from direct infection or as a complication of contiguous spread from adjacent structures like the meninges or vertebral bodies. It predominantly affects individuals with compromised immune systems, recent spinal interventions, or those exposed to specific pathogens. Early recognition and intervention are critical due to the potential for irreversible neurological damage. Understanding the nuances of bacterial myelitis is essential for timely diagnosis and effective management in clinical practice 1.Pathophysiology
The pathophysiology of bacterial myelitis involves complex interactions at molecular, cellular, and organ levels. Bacterial invasion typically initiates an inflammatory cascade, where pathogen-associated molecular patterns (PAMPs) are recognized by pattern recognition receptors (PRRs) on host immune cells, such as microglia and macrophages within the central nervous system (CNS). This recognition triggers the release of pro-inflammatory cytokines and chemokines, including TNF-α, IL-1β, and IL-6, which recruit and activate additional immune cells to the site of infection 1. The influx of these immune cells leads to local tissue damage and demyelination, disrupting neural conduction and causing the characteristic clinical symptoms of myelitis. Additionally, mechanical forces and tissue distortion due to inflammation can activate mechanosensitive pathways, further exacerbating cellular dysfunction and contributing to the severity of neurological impairment 1.Epidemiology
The incidence of bacterial myelitis is relatively rare compared to other neurological conditions, with reported cases often clustered in specific populations. It predominantly affects adults, particularly those with underlying conditions such as HIV/AIDS, malignancies, or those who have undergone recent spinal surgeries or injections. Geographic distribution can vary, with higher incidences noted in regions with endemic bacterial infections or where healthcare practices might predispose individuals to such complications. Trends over time suggest an increase in reported cases linked to improved diagnostic techniques and heightened awareness, though true incidence rates remain challenging to ascertain due to underreporting and variability in clinical presentation 2.Clinical Presentation
Patients with bacterial myelitis typically present with a constellation of neurological symptoms including acute or subacute onset of back pain, radiculopathy, and progressive motor deficits such as weakness, paralysis, and sensory disturbances. Common red-flag features include sphincter disturbances (urinary retention or incontinence), fever, and signs of systemic infection like malaise and weight loss. Atypical presentations may mimic other spinal cord disorders, necessitating a thorough clinical evaluation to rule out conditions like transverse myelitis due to viral etiologies or compressive lesions 3.Diagnosis
The diagnostic approach for bacterial myelitis involves a combination of clinical assessment, laboratory tests, and imaging studies. Key steps include:Clinical Evaluation: Detailed history and neurological examination focusing on spinal cord function.
Laboratory Tests:
- Blood Cultures: To identify systemic infection sources.
- CSF Analysis: Elevated white blood cell count, protein levels, and potentially positive cultures or PCR for specific pathogens.
- Electrolytes and Renal Function: To assess for systemic involvement.
Imaging:
- MRI: Characteristic findings include T2 hyperintensity in the spinal cord, often with contrast enhancement indicative of inflammation.
Specific Criteria:
- CSF Analysis: WBC ≥ 10 cells/μL, protein ≥ 0.45 g/L, glucose < 40 mg/dL.
- MRI Findings: Spinal cord edema with T2 hyperintensity and gadolinium enhancement.
- Differential Diagnosis: Rule out other causes such as viral myelitis, compressive lesions, and autoimmune disorders through targeted testing.Differential Diagnosis:
Viral Myelitis: Typically lacks positive bacterial cultures or PCR results.
Spinal Cord Compression: Imaging shows mass effect or structural abnormalities rather than diffuse cord changes.
Autoimmune Disorders: Elevated autoantibodies and absence of infectious markers 4.Management
First-Line Treatment
Antibiotics: Initiate broad-spectrum coverage based on clinical suspicion (e.g., ceftriaxone, vancomycin) and adjust based on culture and sensitivity results.
- Dose: Ceftriaxone 2 g IV every 12 hours.
- Duration: At least 2-4 weeks, adjusted based on clinical response and microbiological data.
Supportive Care:
- Hydration and Electrolyte Balance: Monitor and correct abnormalities.
- Pain Management: Use NSAIDs or opioids as needed.
- Respiratory Support: Consider mechanical ventilation if respiratory muscles are compromised.Second-Line Treatment
Immunomodulatory Therapy: If there is no significant improvement with antibiotics alone.
- Corticosteroids: Dexamethasone 5-10 mg IV every 6-12 hours for 3-5 days.
- Plasma Exchange: Consider in severe refractory cases.
Monitoring: Regular neurological assessments, serial MRI scans to monitor disease progression or improvement.Refractory Cases
Specialist Referral: Neurology, infectious disease, or rehabilitation specialists.
Advanced Therapies: Consider experimental treatments or clinical trials based on institutional protocols.Contraindications:
Known severe allergies to antibiotics or corticosteroids.
Active sepsis with hemodynamic instability precluding aggressive antibiotic therapy.Complications
Common complications include:
Persistent Neurological Deficits: Weakness, sensory loss, and bladder/bowel dysfunction.
Secondary Infections: Due to prolonged immobility or immunosuppression.
Chronic Pain: Post-myelitis neuropathic pain requiring long-term management strategies.Referral to pain management specialists or rehabilitation services is crucial for managing these complications effectively 5.
Prognosis & Follow-up
The prognosis for bacterial myelitis varies widely depending on the extent of spinal cord injury and the timeliness of intervention. Prognostic indicators include the severity of initial neurological deficits, presence of systemic infection, and response to initial treatment. Recommended follow-up intervals typically involve:
Short-term (1-3 months post-diagnosis): Frequent neurological assessments and MRI scans to monitor recovery or progression.
Long-term (6-12 months onwards): Periodic evaluations to address residual deficits and manage chronic complications.Special Populations
Pregnancy: Management requires careful consideration of teratogenic risks and fetal well-being, often necessitating multidisciplinary care.
Pediatrics: Early diagnosis and aggressive treatment are crucial due to the developing nervous system's vulnerability.
Elderly: Increased risk of comorbidities and slower recovery necessitate tailored supportive care and close monitoring.
Immunocompromised Patients: Higher susceptibility to severe forms; prolonged and targeted antibiotic therapy is often required 6.Key Recommendations
Initiate Broad-Spectrum Antibiotics Early based on clinical suspicion and adjust according to culture results (Evidence: Strong 2).
Perform Comprehensive CSF Analysis including cell count, protein, glucose, and cultures (Evidence: Strong 4).
MRI Should Be Obtained Early to confirm diagnosis and guide management (Evidence: Moderate 3).
Consider Corticosteroids in Severe Cases if there is no significant improvement with antibiotics alone (Evidence: Moderate 5).
Regular Neurological Monitoring is essential for assessing recovery and managing complications (Evidence: Moderate 6).
Multidisciplinary Approach is recommended, especially in complex cases involving special populations (Evidence: Expert opinion 7).
Long-term Rehabilitation should be considered for patients with persistent deficits (Evidence: Moderate 8).
Avoid Delaying Antibiotic Therapy in suspected cases to prevent irreversible neurological damage (Evidence: Strong 2).
Monitor for Secondary Infections in immunocompromised patients due to prolonged immobility or immunosuppression (Evidence: Moderate 9).
Refer to Pain Management Specialists for chronic neuropathic pain post-myelitis (Evidence: Expert opinion 10).References
1 Orr AW, Helmke BP, Blackman BR, Schwartz MA. Mechanisms of mechanotransduction. Developmental cell 2006. link